Brian Hennessy
Allschwil, BL, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Macitentan and phosphodiesterase-5 inhibitor alone or in combination in newly diagnosed pulmonary arterial hypertension: a pooled analysis.
Journal: JHLT open
Published: January 22, 2026
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial.
Journal: Multiple sclerosis and related disorders
Published: November 28, 2024
The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 23, 2022
Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: August 01, 2022
Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Journal: Multiple sclerosis and related disorders
Published: December 24, 2021
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies.
Journal: Neurology
Published: June 11, 2021
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Journal: JAMA neurology
Published: March 29, 2021
Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases.
Journal: Circulation. Cardiovascular quality and outcomes
Published: May 22, 2019
Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 03, 2013
Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study.
Journal: Journal of neurology
Published: September 18, 2013
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
Journal: The Lancet. Neurology
Published: December 08, 2011
Showing 1-11 of 11
Last Updated: 09/26/2026